期刊
ATHEROSCLEROSIS
卷 240, 期 1, 页码 260-271出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2015.03.025
关键词
SLCO1B1; Anti-HMGCR; Statin-related myopathy; Pharmacogenomics
资金
- Pollin Cardiovascular Prevention Fellowship
- Marie-Josee and Henry R. Kravis endowed fellowship
- NIH training grant [T32HL07024]
Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据